AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2531718
Drug: Placebo pre-treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pre-treatment
Trial: 10220271
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of ACD-A
Trial: 2196353
Drug: Furosemide, 4
RxNorm normalized name: Furosemide, 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide, 4 mg/kg in two divided doses on alternate days orally for 8 days
Trial: 357451
Drug: Cue-controlled relaxation
RxNorm normalized name: Relax-DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cue-controlled relaxation therapy
Trial: 31536511
Drug: Silymarin 700
RxNorm normalized name: silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silymarin 700 mg
Trial: 31536511
Drug: Silymarin 420
RxNorm normalized name: silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silymarin 420 mg
Trial: 15483018
Drug: Combined-modality therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined-modality therapy including cyclophosphamide, doxorubicin, methotrexate, fluorouracil, leucovorin, hormonal synchronization with conjugated estrogens and tamoxifen, followed by definitive radiotherapy or mastectomy and adjuvant chemotherapy.
Trial: 15483018
Drug: Combined-modality therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined-modality therapy for stage IIIA breast cancer patients.
Trial: 15483018
Drug: Combined-modality therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined-modality therapy for stage IIIB non-IBC patients.
Trial: 15483018
Drug: Combined-modality therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined-modality therapy for IBC patients.
Trial: 11157314
Drug: Stearic acid
RxNorm normalized name: Stearic Acid
DrugBank: Stearic acid (DB03193)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stearic acid (1 g fat/kg body wt)
Trial: 11157314
Drug: Palmitic acid
RxNorm normalized name: Palmitic Acid
DrugBank: Palmitic Acid (DB03796)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palmitic acid (1 g fat/kg body wt)
Trial: 11157314
Drug: Unsaturated fatty
RxNorm normalized name: omega-3 polyunsaturated fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unsaturated fatty acids (1 g fat/kg body wt)
Trial: 9436720
Drug: Dysport (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dysport (mean dose: 477 units)
Trial: 9436720
Drug: Botox (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botox (mean dose: 152 units)
Trial: 8615058
Drug: 1 alpha,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 alpha, 24 dihydroxyvitamin D3 ointment (4 micrograms/g applied once daily) for 8 weeks
Trial: 8615058
Drug: 1 alpha,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 alpha, 24 dihydroxyvitamin D3 ointment and Placebo
Trial: 788750
Drug: Prorenoate potassium
RxNorm normalized name: Propanoic acid
DrugBank: Propanoic acid (DB03766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prorenoate potassium (40 mg)
Trial: 9418687
Drug: Spironolactone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (100 mg)
Trial: 24102851
Drug: Sequential blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential blood pressure measurement
Trial: 21211729
Drug: leuproreline 11,25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: leuproreline 11,25 mg for 3 years
Trial: 21211729
Drug: radiotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: radiotherapy plus leuproreline 11,25 mg for 3 years
Trial: 19758969
Drug: Enoxaparin (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (0.75 mg/kg)
Trial: 2006593
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg IVB
Trial: 2006593
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg TNB
Trial: 2006593
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg TNB followed by 1 mg TNB at 60 min
Trial: 2006593
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg TNB followed by 0.5 mg TNB at 60 min
Trial: 2006593
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg TNB (divided into 2 doses)
Trial: 2006593
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of TNB and IVB
Trial: 7082535
Drug: Domperidone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone (20 mg) i.v.
Trial: 25810068
Drug: darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: darbepoetin alfa treatment
Trial: 23257490
Drug: Lycopene (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lycopene (8 mg Lycored TM per day in two divided doses of 4 mg each)
Trial: 23257490
Drug: Placebo (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (placebo tablet twice a day)
Trial: 20967981
Drug: Testosterone undecanoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone undecanoate (1 intramuscular injection)
Trial: 20967981
Drug: Vardenafil (on-demand
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vardenafil (on-demand monotherapy for 6 weeks)
Trial: 20967981
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (testosterone undecanoate and vardenafil in the same doses and duration)
Trial: 15857093
Drug: Implants in
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implants in patients with generalized aggressive periodontitis (GAgP)
Trial: 15857093
Drug: Implants in
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implants in patients with generalized chronic periodontitis (GCP)
Trial: 15857093
Drug: Implants in
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implants in periodontally healthy patients
Trial: 15857093
Drug: Teeth and
RxNorm normalized name: SODIUM FLUORIDE 1.1 mg in 1 g DENTAL PASTE, DENTIFRICE [Toms Teeth and Gum Health]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teeth and implants in patients with generalized aggressive periodontitis (GAgP)
Trial: 15857093
Drug: Teeth and
RxNorm normalized name: SODIUM FLUORIDE 1.1 mg in 1 g DENTAL PASTE, DENTIFRICE [Toms Teeth and Gum Health]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teeth and implants in patients with generalized chronic periodontitis (GCP)
Trial: 15857093
Drug: Teeth and
RxNorm normalized name: SODIUM FLUORIDE 1.1 mg in 1 g DENTAL PASTE, DENTIFRICE [Toms Teeth and Gum Health]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teeth and implants in periodontally healthy patients
Trial: 12055814
Drug: Mebendazole 500
RxNorm normalized name: mebendazole 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mebendazole 500 mg
Trial: 19769793
Drug: Haplotype comprising
RxNorm normalized name: Synthetic surfactant comprised of DPPC, POPG Na, synthetic SP-C analogue and synthetic SP-B analogue
DrugBank: CHF5633 (DB18696)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haplotype comprising alleles rs659366-G, rs653529-A, rs15763-G and rs1726745-A
Trial: 19769793
Drug: Haplotype comprising
RxNorm normalized name: Synthetic surfactant comprised of DPPC, POPG Na, synthetic SP-C analogue and synthetic SP-B analogue
DrugBank: CHF5633 (DB18696)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haplotype comprising alleles rs3781907-G, rs11235972-A, and rs1800849-T
Trial: 15675259
Drug: Intranasal sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal sufentanil 20 microg and intranasal midazolam 0.3 mg/kg
Trial: 15675259
Drug: Intranasal ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal ketamine 5 mg/kg and intranasal midazolam 0.3 mg/kg
Trial: 12495409
Drug: High-voltage pulsed
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-voltage pulsed current (HVPC) (100 microseconds, 150 V, 100 Hz) for 45 minutes, 3 times weekly, for 4 weeks
Trial: 12495409
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment for 45 minutes, 3 times weekly, for 4 weeks
Trial: 1718692
Drug: Gallopamil 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gallopamil 0.4 mg
Trial: 29369348
Drug: Eslicarbazepine acetate
RxNorm normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eslicarbazepine acetate (800 mg)
Trial: 29369348
Drug: Carbamazepine-CR (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine-CR (200 mg BID)
Trial: 29369348
Drug: Eslicarbazepine acetate
RxNorm normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eslicarbazepine acetate (1200 mg)
Trial: 29369348
Drug: Carbamazepine-CR (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine-CR (400 mg BID)
Trial: 23364045
Drug: Oral Function
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Function Improvement Exercises (3 times a week for a total of 24 times)
Trial: 19939369
Drug: Combined sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined sequential acidic and less‐acidic FSH
Trial: 15332095
Drug: Activated device
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated device (meibomian therapy with latent heat)
Trial: 8132436
Drug: Paroxetine (20-30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (20-30 mg daily)
Trial: 8132436
Drug: Sulpiride (200-400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulpiride (200-400 mg daily)
Trial: 30711649
Drug: Pembrolizumab 2
RxNorm normalized name: pembrolizumab 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 2 or 10 mg/kg every 3 weeks
Trial: 29142982
Drug: Etelcalcetide 5
RxNorm normalized name: etelcalcetide 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etelcalcetide 5 mg
Trial: 29142982
Drug: Etelcalcetide 10
RxNorm normalized name: etelcalcetide 10 MG per 2 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etelcalcetide 10 mg
Trial: 29142982
Drug: Etelcalcetide 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etelcalcetide 20 mg
Trial: 29142982
Drug: Etelcalcetide 2.5
RxNorm normalized name: ETELCALCETIDE 2.5MG/0.5ML INJ,SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etelcalcetide 2.5 mg (multiple dose)
Trial: 29142982
Drug: Etelcalcetide 5
RxNorm normalized name: etelcalcetide 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etelcalcetide 5 mg (multiple dose)
Trial: 29142982
Drug: Etelcalcetide (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etelcalcetide (all doses)
Trial: 21490520
Drug: Circumferential injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Circumferential injection of local anesthetic (30 mL admixture of 1:1 lidocaine 2%/bupivacaine 0.5% with 1:200,000 epinephrine)
Trial: 21490520
Drug: Single-location injection
RxNorm normalized name: Potassium cation
DrugBank: Potassium cation (DB01345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-location injection of local anesthetic (30 mL admixture of 1:1 lidocaine 2%/bupivacaine 0.5% with 1:200,000 epinephrine)
Trial: 11014136
Drug: Evidence-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evidence-based treatment recommendations for bite wounds
Trial: 9358138
Drug: Low-dose inhaled
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose inhaled budesonide (400 microg) plus theophylline (250 or 375 mg depending on body weight)
Trial: 9358138
Drug: High-dose inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose inhaled budesonide (800 microg)
Trial: 9358138
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (low-dose budesonide plus theophylline and high-dose budesonide)
Trial: 8199605
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of zinc gluconate daily
Trial: 30458930
Drug: ME-401 10
RxNorm normalized name: LIMOSILACTOBACILLUS FERMENTUM ME-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ME-401 10 mg
Trial: 30458930
Drug: ME-401 60
RxNorm normalized name: LIMOSILACTOBACILLUS FERMENTUM ME-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ME-401 60 mg
Trial: 30458930
Drug: ME-401 150
RxNorm normalized name: LIMOSILACTOBACILLUS FERMENTUM ME-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ME-401 150 mg
Trial: 30458930
Drug: ME-401 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ME-401 (various doses)
Trial: 30458930
Drug: ME-401 once
RxNorm normalized name: LIMOSILACTOBACILLUS FERMENTUM ME-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ME-401 once daily 60 mg
Trial: 28190787
Drug: Riociguat up
RxNorm normalized name: Riociguat
DrugBank: Riociguat (DB08931)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Riociguat up to 2.5 mg 3 times a day
Trial: 19538718
Drug: Combination Disease
RxNorm normalized name: LYME DISEASE VACCINE
DrugBank: Lyme disease vaccine (recombinant OspA) (DB00045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination Disease Modifying Antirheumatic Drug therapy
Trial: 19538718
Drug: Monotherapy methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Monotherapy methotrexate
Trial: 19538718
Drug: Disease Modifying
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disease Modifying Antirheumatic Drug of various intensities
Trial: 19538718
Drug: Non-steroidal anti-inflammatory
RxNorm normalized name: Non-steroidal anti-inflammatory agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-steroidal anti-inflammatory drugs, hydroxychloroquine, and a single dose of corticosteroids
Trial: 16951642
Drug: Structured treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured treatment interruption (STI) for 4 months
Trial: 11776481
Drug: Acetaminophen 1000
RxNorm normalized name: acetaminophen 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 1000 mg, 4 times daily for 2 consecutive days
Trial: 8496384
Drug: Computerised systems
RxNorm normalized name: Synthetic surfactant comprised of DPPC, POPG Na, synthetic SP-C analogue and synthetic SP-B analogue
DrugBank: CHF5633 (DB18696)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computerised systems for warfarin control
Trial: 8496384
Drug: Computerised dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computerised dosage programs
Trial: 8496384
Drug: Traditional dosing
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional dosing method by experienced medical staff
Trial: 24880749
Drug: Lithium (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium (500 mg, twice a day)
Trial: 15596954
Drug: Rhythm control
RxNorm normalized name: ALUMINUM ZIRCONIUM TRICHLOROHYDREX GLY 180 mg in 1 g TOPICAL STICK [ZUSKA RHYTHM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhythm control using antiarrhythmic drugs
Trial: 12527962
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive (OC) users during days 15-28
Trial: 12527962
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive (OC) users during days 1-14
Trial: 8750478
Drug: Intravenous multidrug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous multidrug chemotherapy
Trial: 27780197
Drug: Any dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any dose of dextrose gel
Trial: 27565734
Drug: 1800 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1800 mg/day of eicosapentaenoic acid (EPA), n = 53
Trial: 24953916
Drug: Bupivacaine moistened
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine moistened dressing (12 mL/100 cm2 of 0.25% bupivacaine solution)
Trial: 23297552
Drug: Series of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Series of formulas changed daily according to TCM syndrome
Trial: 8970500
Drug: Lithium, starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium, starting at 15 mg/kg of body weight, dosage increase every 3 to 4 days until response or serum level of 1.2 to 1.4 mEq/L
Trial: 8970500
Drug: Valproate (divalproex),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valproate (divalproex), initiated at 20 mg/kg of body weight
Trial: 8970500
Drug: Carbamazepine, starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine, starting at 200 mg once or twice daily with slow dosage escalation
Trial: 1713269
Drug: murine monoclonal
RxNorm normalized name: 131I-BC8 monoclonal antibody (Anti-CD45 murine monoclonal antibody radiolabeled with 131I
DrugBank: Apamistamab iodine I-131 (DB16748)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: murine monoclonal anti‐CD4 (B‐F5) antibody (10 mg/day, 15 mg/day, 20 mg/day) for 10 consecutive days
Trial: 6711781
Drug: Slow release
RxNorm normalized name: Slow Release Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow release morphine sulphate tablets (MST, 20 mg)
Trial: 30715637
Drug: GaAlAs laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GaAlAs laser treatment (wavelength 830 nm, 30 mW, power density 0.84 W/cm2)
Trial: 30715637
Drug: LED treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LED treatment (wavelength 850 nm, 48 mW, power density 1.05 W/cm2)
Trial: 30715637
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of laser and LED therapies
Trial: 30715637
Drug: Both therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both therapies (laser and LED)
Trial: 17272969
Drug: Rivastigmine 6
RxNorm normalized name: rivastigmine 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivastigmine 6 mg treatment
Trial: 15665005
Drug: Home based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home based medication review by pharmacists (two home visits within two weeks and eight weeks of discharge)
Trial: 15665005
Drug: Home based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home based medication review by pharmacists
Trial: 10453419
Drug: High-dose pancreatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose pancreatin
Trial: 10453419
Drug: Standard-dose pancreatin
RxNorm normalized name: Pancreatin
DrugBank: Pancrelipase (DB00085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose pancreatin
Trial: 24000709
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for community-acquired pneumonia with hypertension
Trial: 24000709
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (patients with community-acquired pneumonia during treatment)
Trial: 22619907
Drug: 75-mg of
RxNorm normalized name: povidone-iodine 75 MG/ML [Betagen brand of povidone-iodine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75-mg of diclofenac sodium
Trial: 9629994
Drug: Mizolastine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mizolastine (10 mg o.d.) and digoxin (0.25 mg o.d.)
Trial: 9629994
Drug: Placebo and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo and digoxin (0.25 mg o.d.)
Trial: 28929343
Drug: Isomaltulose (8%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isomaltulose (8% carbohydrate-electrolyte drink, 20 g h-1)
Trial: 28929343
Drug: Maltodextrin (8%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maltodextrin (8% carbohydrate-electrolyte drink, 20 g h-1)
Trial: 1449044
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human growth hormone (r‐hGH) (0.1 IU/kg sc twice daily)
Trial: 29413685
Drug: Cisplatin 25
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 25 mg/m2 and Gemcitabine 1000 mg/m2 with Panitumumab (arm A)
Trial: 29413685
Drug: Cisplatin 25
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 25 mg/m2 and Gemcitabine 1000 mg/m2 without Panitumumab (arm B)
Trial: 17487649
Drug: CE/MPA 0.625/2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CE/MPA 0.625/2.5 mg/day
Trial: 17487649
Drug: CE/MPA 0.45/1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CE/MPA 0.45/1.5 mg/day
Trial: 17487649
Drug: CE/MPA 0.3/1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CE/MPA 0.3/1.5 mg/day